Featured
The CSRC launched a series of policies tightening IPOs
2023年8月27日，在万众期待之下，证监会推出了一系列救市政策，包括降低印花税、IPO收紧、降低两融保证金、规范减持等多项内容。
The China Securities Regulatory Commission coordinates the balance of the primary and secondary markets and optimizes the regulatory arrangements for IPOs and refinancing
The China Securities Regulatory Commission (CSRC) announced on 27 August that the CSRC fully considers the current market situation, improves the counter-cyclical adjustment mechanism of the primary and secondary markets, and makes arrangements around reasonably grasping the rhythm of IPO and refinancing.
Pfizer Fights Claim It Fired Executive Who Raised Graft Concerns
Pfizer Inc. is fighting a lawsuit by a former employee who alleges he was fired after he raised concerns about the company paying tens of millions of dollars to government officials in China, where the drugmaker’s business practices have been under US review.
国内首家申请上市！荃信生物/华东医药乌司奴单抗生物类似药获受理
“8月11日，江苏荃信生物医药股份有限公司（以下简称“荃信生物”）同华东医药(000963.SZ)全资子公司杭州中美华东制药有限公司（以下简称“中美华东”）联合开发的乌司奴单抗生物类似药（研发代码：QX001S/HDM3001）获得国家药品监督管理局（NMPA）签发的《受理通知书》（受理号：CXSS2300065），用于治疗成年中重度斑块状银屑病。 QX001S/HDM3001注射液是强生公司Stelara®（喜达诺®，乌司奴单抗注射液）的生物类似药，其作用机理为阻断IL-12和IL-23共有的p40亚基与靶细胞表面的IL-12Rβ1受体蛋白的结合，从而抑制IL-12和IL-23介导的信号传导和细胞因子级联反应。IL-12和IL-23是两种天然存在的细胞因子，在免疫介导的炎症性疾病中发挥着关键作用。 银屑病是一种慢性、复发性、炎症性疾病，主要累及皮肤和关节系统，目前尚无法治愈，需长期甚至终身治疗。根据弗若斯特沙利文的资料，2021年中国银屑病的患病人数为670万人，预计于2030年将达到690万。斑块银屑病约占所有银屑病病例的80%～90%，是银屑病中最常见的类型。目前，生物治疗已经成为银屑病的主要治疗方法之一，在治疗重症、难治以及特殊类型银屑病方面发挥了积极而有效的作用。” Continue reading at the original source, linked here.
Schroders Capital to expand private equity operations in China
Schroders Capital is close to launching its first onshore private equity offering in China, as it looks to capitalise on the growing renminbi market.
估值超8.29亿美元！宜明昂科港股过聆讯
“8月14日，宜明昂科港股上市正式通过聆讯，预计不久后将成为今年少有的biotech上市股。中金公司和摩根士丹利担任联席保荐人。（关注公众号后台回复“宜明昂科”获取招股书PDF） 宜明昂科核心产品IMM0306（CD47×CD20）、IMM2902（CD47×HER2）及IMM2520（CD47×PD-L1）均为三个基于CD47的双特异性分子。其他10款处于不同开发阶段可靶向关键先天及适应性免疫靶点的候选药物，包括CD24抗体、CD47×CD24双抗、PD-L1×CD24双抗及3款处于临床及IND阶段的适应性免疫药物（VEGF×PD-L1双抗、CTLA-4 ADCC增强型单抗、CD70单抗），其他先天免疫检查点早期靶点包括IL-8抗体、NKG2A抗体、PSGL-1抗体。 近年来除CD47外，宜明昂科还选择并验证了另一个先天免疫检查点CD24。正在围绕CD24开发一款处于IND准备阶段及多款发现阶段及临床前阶段的候选药物，每一款都有可能成为同类中最早进入临床阶段的全球少数首创药物。2022年Pheast Therapeutics完成7600万美元A轮融资。融资由ARCH和Catalio Capital Management领投。这家临床前公司从斯坦福大学Irv Weissman教授的实验室中分离出来，专注于免疫肿瘤学。Weissman和Ravi Majeti博士是Forty Seven的联合创始人，该公司于2020年被Gilead Sciences收购。该公司的主要项目针对表面蛋白CD24，这是一种被许多癌症（包括卵巢癌和乳腺癌）征用的“不要吃我”信号，以避免被肿瘤内巨噬细胞检测和清除” Continue reading at the original source, linked here.
Jiangsu Hengrui inks deal with One Bio for ex-China rights to SHR-1905
Jiangsu Hengrui Pharmaceuticals has out-licensed global rights, excluding China, for its anti-TSLP monoclonal antibody SHR-1905 to One Bio.
Kelun-Biotech announces that a Phase III clinical trial of core product SKB264 (MK-2870, TROP2-ADC) in patients with unresectable locally advanced, recurrent or metastatic TNBC who have failed second-line or above prior standard of care has met its primary endpoint
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. ("Kelun-Biotech", HKEX: 6990.HK) announced today that its innovative TROP2-ADC (SKB264, also known as MK-2870) met the primary endpoint in the randomized, controlled, open-label, multi-center Phase III clinical trial of SKB264 for injection versus investigator selected regimens in patients with unresectable locally advanced, recurrent or metastatic triple-negative breast cancer (TNBC) who have failed second-line or above prior standard of care.
Diamond Equity Research Initiates Coverage on YS Biopharma Co., Ltd. (NASDAQ: YS)
Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has initiated coverage of YS Biopharma Co., Ltd. (NASDAQ: YS).
Pfizer faces whistleblower lawsuit from former compliance manager who says he flagged possible fraud in China
Frank Han, the former director of global compliance analytics at Pfizer, has filed a civil complaint against the drugmaker.
